Ontology highlight
ABSTRACT: Introduction
Immune checkpoint inhibitors (ICIs) are increasingly used to treat advanced cancer. Rheumatoid arthritis (RA) is associated with an increased risk of malignancies; however, patients with RA have been excluded from ICI trials. In this study, we evaluated risk of toxicity after initiation of ICI treatment in RA patients.Methods
We conducted a single-institution, medical records review analysis to assess the incidence of immune-related adverse events (irAEs) and autoimmune disease (AID) flares among patients with AIDs treated with ICIs from 2011 to 2018. A subgroup analysis for RA patients was performed with frequencies of irAEs and AID flares reported.Results
Twenty-two patients with RA who were treated with ICI for malignancy were identified. At the time
SUBMITTER: Efuni E
PROVIDER: S-EPMC7374048 | biostudies-literature | 2021 Oct
REPOSITORIES: biostudies-literature